References
1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke
Statistics-2019 Update: A Report From the American Heart Association.Circulation. 2019;139(10):e56-e528.
2. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation:
Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res.2017;120(9):1501-1517.
3. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence,
and lifetime risk of atrial fibrillation in China: new insights into the
global burden of atrial fibrillation. Chest. 2015;147(1):109-119.
4. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial
fibrillation among Asians, Hispanics, blacks, and whites.Circulation. 2013;128(23):2470-2477.
5. O’Neal WT, Tanner RM, Efird JT, et al. Atrial fibrillation and
incident end-stage renal disease: The REasons for Geographic And Racial
Differences in Stroke (REGARDS) study. International journal of
cardiology. 2015;185:219-223.
6. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment
associated with atrial fibrillation: a meta-analysis. Annals of
internal medicine. 2013;158(5 Pt 1):338-346.
7. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident
atrial fibrillation and risk of end-stage renal disease in adults with
chronic kidney disease. Circulation. 2013;127(5):569-574.
8. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial
fibrillation and congestive heart failure and their joint influence on
mortality: the Framingham Heart Study. Circulation.2003;107(23):2920-2925.
9. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic
drug therapy and radiofrequency catheter ablation in patients with
paroxysmal atrial fibrillation: a randomized controlled trial.Jama. 2010;303(4):333-340.
10. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs
Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac
Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized
Clinical Trial. Jama. 2019;321(13):1261-1274.
11. Mont L, Bisbal F, Hernandez-Madrid A, et al. Catheter ablation vs.
antiarrhythmic drug treatment of persistent atrial fibrillation: a
multicentre, randomized, controlled trial (SARA study). European
heart journal. 2014;35(8):501-507.
12. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for
Atrial Fibrillation with Heart Failure. The New England journal of
medicine. 2018;378(5):417-427.
13. Pappone C, Augello G, Sala S, et al. A randomized trial of
circumferential pulmonary vein ablation versus antiarrhythmic drug
therapy in paroxysmal atrial fibrillation: the APAF Study. Journal
of the American College of Cardiology. 2006;48(11):2340-2347.
14. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of
pulmonary veins for paroxysmal atrial fibrillation: first results of the
North American Arctic Front (STOP AF) pivotal trial. Journal of
the American College of Cardiology. 2013;61(16):1713-1723.
15. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus
antiarrhythmic drugs for atrial fibrillation: the A4 study.Circulation. 2008;118(24):2498-2505.
16. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial
fibrillation with antiarrhythmic drugs or radiofrequency ablation: two
systematic literature reviews and meta-analyses. Circulation
Arrhythmia and electrophysiology. 2009;2(4):349-361.
17. Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of Atrial
Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in
the CABANA Trial. Journal of the American College of Cardiology.2020;75(25):3105-3118.
18. Jin MN, Kim TH, Kang KW, et al. Atrial Fibrillation Catheter
Ablation Improves 1-Year Follow-Up Cognitive Function, Especially in
Patients With Impaired Cognitive Function. Circulation Arrhythmia
and electrophysiology. 2019;12(7):e007197.
19. Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after
catheter ablation of atrial fibrillation. Circulation.2011;124(22):2380-2387.
20. Fichtner S, Deisenhofer I, Kindsmuller S, et al. Prospective
assessment of short- and long-term quality of life after ablation for
atrial fibrillation. Journal of cardiovascular electrophysiology.2012;23(2):121-127.
21. Wang Q, Zhang XD, Liu X, Yang YQ. Renal function after repeat
catheter ablation for long-standing persistent atrial fibrillation : Low
CHA2DS2-VASc score and sinus rhythm predict improved renal function.Herz. 2016;41(4):331-341.
22. Park JW, Yang PS, Bae HJ, et al. Five-Year Change in the Renal
Function After Catheter Ablation of Atrial Fibrillation. Journal
of the American Heart Association. 2019;8(17):e013204.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate
glomerular filtration rate.
24. Yang B, Jiang C, Lin Y, et al. STABLE-SR (Electrophysiological
Substrate Ablation in the Left Atrium During Sinus Rhythm) for the
Treatment of Nonparoxysmal Atrial Fibrillation: A Prospective,
Multicenter Randomized Clinical Trial. Circulation Arrhythmia and
electrophysiology. 2017;10(11).
25. National Kidney F. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classification, and stratification. Am
J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
26. Chapter 2: Definition, identification, and prediction of CKD
progression. Kidney Int Suppl (2011). 2013;3(1):63-72.
27. Turin TC, James M, Ravani P, et al. Proteinuria and rate of change
in kidney function in a community-based population. Journal of the
American Society of Nephrology : JASN. 2013;24(10):1661-1667.
28. Kidney Disease Outcomes Quality I. K/DOQI clinical practice
guidelines on hypertension and antihypertensive agents in chronic kidney
disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-290.
29. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the
diagnosis and management of atrial fibrillation developed in
collaboration with the European Association of Cardio-Thoracic Surgery
(EACTS). European heart journal. 2020.
30. Pandey A, Kim S, Moore C, et al. Predictors and Prognostic
Implications of Incident Heart Failure in Patients With Prevalent Atrial
Fibrillation. JACC Heart Fail. 2017;5(1):44-52.
31. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial
fibrillation type on the risk of thromboembolism, mortality, and
bleeding: a systematic review and meta-analysis. European heart
journal. 2016;37(20):1591-1602.
32. Link MS, Giugliano RP, Ruff CT, et al. Stroke and Mortality Risk in
Patients With Various Patterns of Atrial Fibrillation: Results From the
ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next
Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction
48). Circulation Arrhythmia and electrophysiology. 2017;10(1).
33. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al.
Radiofrequency ablation as initial therapy in paroxysmal atrial
fibrillation. The New England journal of medicine.2012;367(17):1587-1595.
34. Pallisgaard JL, Gislason GH, Hansen J, et al. Temporal trends in
atrial fibrillation recurrence rates after ablation between 2005 and
2014: a nationwide Danish cohort study. European heart journal.2018;39(6):442-449.
35. Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or
Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous
Monitoring: A Randomized Clinical Trial. Circulation.2019;140(22):1779-1788.
Table 1. Clinical characteristics at baseline during the initial
admission before RFCA.